|
|
|
Thursday, November 20, 2008
 Latest
Acute Leukemia News Headlines
|
|
Acute Leukemia News Headlines
|
|
|
|
|
|
|
|
|
|
|
All Recent Acute Leukemia News Headlines |
|
|
|
|
|
|
Anaphylaxis and superior vena cava thrombus in a pediatric patient with acute lymphoblastic leukemia.
Page: 771DOI: 10.1097/PEC.0b013e31818cAuthors: Creel, Amy M. MD *; Crawford, David MD +; Prabhakaran, Priya MD * (Source: Pediatric Emergency Care)...
POSTED 11/19/2008 at 01:10 AM --
|
Height growth during adolescence and final height after haematopoietic sct for childhood acute leukaemia: the impact of a conditioning regimen with bu or tbi
Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI
Bone Marrow Transplantation advance online publication, November 17, 2008. doi:10.1038/bmt.2008.370
Authors: F Bernard, P Bordigoni, M-C Simeoni, V Barlogis, A Contet, A Loundou, I Thuret, B Leheup, H Chambost, B Play, P Auquier
& G Michel (Source: Bone Marrow Transplantation)...
POSTED 11/16/2008 at 11:00 PM --
|
Inexplicable suppression of hepatic uptake of gallium-67, a case report
We describe here a case report of a patient with acute lymphocytic leukemia in whom hepatic gallium-67 (Ga-67) uptake was
suppressed. The patient, was hospitalized with increasing dyspnea. In Ga-67 scintigraphy, there was no hepatic uptake, although
other physiological uptake was clearly observed. In addition, the scintigraphy showed increased accumulation in the right
lung consistent with infection. We considered possible reasons for these findings. The patient had no history of chemotherapy
or blood transfusion, and his iron metabolism was almost normal. He was not receiving any medication which might reduce hepatic
blood flow. Blood chemistry suggested normal hepatic and renal function. The patient died from pneumonia 6 weeks later. The
autopsy revealed extensive infiltration of t......
POSTED 11/16/2008 at 05:46 AM --
|
Acute leukaemia following renal transplantation
This report further suggests that the leukaemia that develops in such patients may respond to
standard therapy, and that such treatment does not compromise the transplanted kidney.
Content Type Journal ArticleCategory PaperDOI 10.1007/BF02988836Authors
Milayna Subar, North Central Bronx Hospital Division of Hematology, Department of Medicine 3424 Kossuth Avenue Room 10C-03 10467 Bronx New York USARasim Gucalp, Albert Einstein Cancer Center Montefiore Medical Center Bronx New York USAJudith Benstein, St Luke’s- Roosevelt Hospital Center Division of Nephrology, Department of Medicine New York City USAGail Williams, Columbia Presbyterian Medical Center Division of Nephrology, Department of Medicine New York City USAPeter H. Wiernik, Albert Einstein Cancer Center Montefiore Medical Cen......
POSTED 11/16/2008 at 05:29 AM --
|
Nuclear factor-{kappa}b modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia.
CONCLUSIONS: These results show the feasibility of NF-kappaB modulation in conjunction with induction chemotherapy for patients with AML using inexpensive readily available medications. A follow-up study to determine the effects of NF-kappaB modulation on clinical end points is warranted.
PMID: 19010875 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)...
POSTED 11/14/2008 at 11:00 PM --
|
Role of the erythropoietin receptor in etv6/runx1-positive acute lymphoblastic leukemia.
CONCLUSIONS: Our data suggest that ETV6/RUNX1 leads to EPOR up-regulation and that activation by EPO might be of relevance to the biology of this leukemia subtype. Further studies are, however, needed to assess the clinical implications of its apoptosis-modulating properties.
PMID: 19010836 [PubMed - in process] (Source: Clinical Cancer Research)...
POSTED 11/14/2008 at 11:00 PM --
|
Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells.
This article discusses the balance between LAA-driven leukemia cell expansion and the elimination of these cells through attacks on LAAs by the immune system. Current knowledge of the function and CD8(+) T-cell recognition of LAAs is reviewed and an outlook is given on how to improve T-cell responses to LAAs in acute myeloid leukemia cells.
PMID: 19010831 [PubMed - in process] (Source: Clinical Cancer Research)...
POSTED 11/14/2008 at 11:00 PM --
|
Case of patient "cured" of hiv baffles doctors
Doctors and experts are baffled by the case of a 42-year old male American patient living in Berlin whose 10-year long HIV infection appears to have been "cured" by a bone marrow transplant given to treat his acute myeloid leukemia. (Source: Health News from Medical News Today)...
POSTED 11/14/2008 at 10:00 AM --
|
Synergistic proapoptotic activity of recombinant trail plus the akt inhibitor perifosine in acute myelogenous leukemia cells
To potentiate the response of acute myelogenous leukemia (AML) cells to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) cytotoxicity, we have examined the efficacy of a combination with perifosine, a novel phosphatidylinositol-3-kinase (PI3K)/Akt signaling inhibitor. The rationale for using such a combination is that perifosine was recently described to increase TRAIL-R2 receptor expression and decrease the cellular FLICE-inhibitory protein (cFLIP) in human lung cancer cell lines. Perifosine and TRAIL both induced cell death by apoptosis in the THP-1 AML cell line, which is characterized by constitutive PI3K/Akt activation, but lacks functional p53. Perifosine, at concentrations below IC50, dephosphorylated Akt and increased TRAIL-R2 levels, as shown by Western blot, ......
POSTED 11/13/2008 at 11:00 PM --
|
Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
In conclusion, these results may support the idea that methylated metabolites of As(2)O(3) contribute to the efficacy of arsenic in APL patients. These results also suggest that detailed studies on the pharmacokinetics as well as the pharmacodynamics of As(2)O(3) in the blood cells from APL patients should be carried out to provide an effective treatment protocol.
PMID: 19009285 [PubMed - as supplied by publisher] (Source: Analytical and Bioanalytical Chemistry)...
POSTED 11/13/2008 at 11:00 PM --
|
Evolution of multiple cytogenetic clones and leukemic transformation in a case of myelodysplastic syndrome
Abstract The cytogenetic follow-up of a case of refractory anemia with excess of blasts (RAEB) that rapidly evolved to acute myeloblastic
leukemia (Ml-FAB type) is described. Bone marrow analysis at presentation revealed two chromosomally abnormal clones that
shared an interstitial deletion of the long arm of chromosome 5 (5q−) and a terminal deletion of the short arm of chromosome
12 (12p-), but that differed from one another in the localization of a very similar segment of chromosome 17 (i.e. 17q11−12qter)
on two clearly distinct karyotypic sites: 2q37 and 17q25. Fourteen percent of the metaphases examined bore the 2q+ marker
and 38% the 17q+ marker; the remaining cells had a normal karyotype. A second study carried out 4 months later, at onset of
the acute phase, re......
POSTED 11/13/2008 at 09:55 AM --
|
Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia
Abstract Thirty-seven patients (median age 50 yr, range 17–82) with acute myeloid leukemia (AML) received intensive induction treatment
with amsacrine, cytarabine and etoposide in combination. Nine of the patients were refractory to previous induction therapy,
15 relapsed during or after treatment with daunorubicin and cytarabine, 13 had AML after previous hématologic disorders. Eleven
of the patients with AML after previous hematologic disorders had been treated with cytotoxic drugs.
Toxicity was substantial, but complete remission (CR) was achieved in 33% of patients with refractory AML, 47% of patients
with AML in relapse, 54% of patients with AML after antecedent blood disorder. CR duration was 15 weeks (median). Patients
with AML of FAB types M4 and M5 entered re......
POSTED 11/13/2008 at 09:55 AM --
|
Multimarker approach to evaluation of cardiac toxicity during preparative regimen and hematopoietic cell transplantation.
Authors: Horacek JM, Tichy M, Pudil R, Jebavy L, Zak P, Ulrychova M, Slovacek L, Maly J
Cardiac toxicity of preparative regimen (PR) containing high-dose Cyclophosphamide (120 mg/kg) followed by hematopoietic cell transplantation (HCT) was evaluated with 6 biomarkers of cardiac injury: N-terminal pro brain natriuretic peptide (NT-proBNP), creatine kinase MB (CK-MB mass), cardiac troponins (cTnT, cTnI), heart-type fatty acid binding protein (H-FABP), glycogen phosphorylase BB (GPBB). Twenty-three patients (mean age 44.5+/-10.6 years, 15 males) with acute leukemia were studied. All biomarkers were measured the day before PR, the day after PR, the day after HCT and 14 days after HCT. We found NT-proBNP elevations above 500 ng/L in 6 (26.1 %) patients after PR, in 9 (39.1 %) after HCT and ......
POSTED 11/13/2008 at 09:13 AM --
|
Normal maturation sequence of immunoglobulin light and heavy chains in hematogone stages 1, 2 and 3 in acute leukemia after treatment.
Authors: Babusikova O, Zeleznikova T
The cellular diversity of bone marrow samples was studied by using multi-dimensional cluster analysis of six-parametric flow cytometry data (four CD, forward scatter and side scatter), focusing mainly on acute leukemia blast cells and regeneration of normal B-cells, hematogones. This approach should enhance the ability to study normal hematopoiesis, and to identify and monitor hematopoietic disorders. The study was performed on a homogeneous group of patients (mainly children), all of them after finishing complete therapy for AL, mostly B-ALL. In all of these patients complete pattern of all three individual Hg stages was present. Maturation spectra of surface immunoglobulin kappa (sIgkappa) and lambda (sIglambda) light chains and IgM, IgA heavy cha......
POSTED 11/13/2008 at 09:13 AM --
|
Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with nup98-hoxa9.
We report a 29-year-old Japanese male with acute myelogenous leukemia (AML)-M4 with a cryptic t(7;11)(p15;p15), in which a chimeric NUP98-HOXA9 fusion was detected by polymerase chain reaction analysis and a chromosomal analysis showed 46,XY. The patient received intensive chemotherapy and underwent autologous stem cell transplantation, and remission was confirmed by the disappearance of NUP98-HOXA9. However, 6 months after transplantation, the patient relapsed; NUP98-HOXA9 was detected again and karyotypic analysis revealed 46,XY, t(1;21)(p32;q22). Fluorescent in situ hybridization (FISH) analysis using an AML1-ETO translocation dual probe, showed that the 21q22 breakpoint involved AML1 locus. A retrospective FISH analysis showed that t(1;21) was absent at onset. This is the first reporte......
POSTED 11/12/2008 at 11:00 PM --
|
Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
Histopathological Response of Transitional Cell Carcinoma to Arsenic Trioxide during the Treatment of Concurrently Diagnosed Acute Promyelocytic Leukaemia.
Clin Oncol (R Coll Radiol). 2008 Dec;20(10):769-71
Authors: Krishna R
PMID: 18995171 [PubMed - in process] (Source: Clinical Oncology)...
POSTED 11/12/2008 at 07:39 AM --
|
Methotrexate-associated alterations of the folate and methyl-transfer pathway in the csf of all patients with and without symptoms of neurotoxicity
Severe neurotoxicity has been observed after systemic high-dose and intrathecal methotrexate (MTX) treatment. The role of biochemical MTX-induced alterations of the folate and methyl-transfer pathway in the development of neurotoxic symptoms is not yet fully elucidated.MTX, 5-methyltetrahydrofolate, calcium folinate, S-adenosylmethionine, and S-adenosylhomocysteine were measured in the cerebrospinal fluid (CSF) of 29 patients with acute lymphoblastic leukemia (ALL) who were treated with high-dose MTX (5 g/m2) followed by calcium folinate rescue (3 × 15 mg/m2) and/or intrathecal (8-12 mg) MTX. Two patients developed subacute MTX-associated neurotoxicity. CSF was obtained by lumbal puncture 1-3 weeks after administration of MTX and shortly after the occurrence of neurotoxicity. The analytes......
POSTED 11/11/2008 at 11:00 PM --
|
Variability in responsiveness to lovastatin of the primitive cd34+ aml subfraction compared to normal cd34+ cells
Abstract In the present study, we questioned whether the cholesterol synthesis inhibitor lovastatin potentiates the cytotoxicity of
chemotherapeutic agents in the primitive CD34+ subpopulation of acute myeloid leukemia (AML) cells. AML mononuclear cells (n = 17) were sorted in CD34+ and CD34− fractions and compared to normal CD34+/− cells (n = 7). The percentage of surviving cells upon exposure to lovastatin (25–100 μM) and/or chemotherapeutics (cytarabin or daunorubicin)
was determined with a luminescent cell viability assay. The results demonstrate that the primitive CD34+ subpopulation of normal and AML cells displayed a higher sensitivity to lovastatin than the more mature CD34− subpopulation. The combination of lovastatin and chemotherapeutics result......
POSTED 11/11/2008 at 01:50 AM --
|
Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d
-[4-thio-arabinofuranosyl]-cytosine
Conclusions These studies provide a rationale for clinical trials using this combination in the treatment of acute leukemias as well as
solid tumors and suggest that this combination would exhibit greater antitumor activity than that of clofarabine plus araC.
Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-008-0862-zAuthors
William B. Parker, Southern Research Institute 2000 Ninth Avenue South Birmingham AL 35205 USASue C. Shaddix, Southern Research Institute 2000 Ninth Avenue South Birmingham AL 35205 USAKaren S. Gilbert, Southern Research Institute 2000 Ninth Avenue South Birmingham AL 35205 USARodney V. Shepherd, Southern Research Institute 2000 Ninth Avenue South Birmingham AL 35205 USAWilliam R. Waud, Southern Research Institute 2000 Ninth ......
POSTED 11/11/2008 at 01:50 AM --
|
The presence of cd56/cd16 in t-cell acute lymphoblastic leukaemia correlates with the expression of cytotoxic molecules and is associated with worse response to treatment
Some cases of T-cell acute lymphoblastic leukaemia (ALL) express markers found in natural-killer (NK) cells, such as CD56 and CD16. Out of 84 T-cell ALL cases diagnosed at our Institution, CD56 and/or CD16 was detected in 24 (28·5%), which we designated T/NK-ALL group. Clinical features, laboratory characteristics, survival and expression of cytotoxic molecules were compared in T/NK-ALL and T-ALL patients. Significant differences were observed regarding age (24·9 vs. 16·4 years in T/NK-ALL and T-ALL, respectively, P = 0·006) and platelet counts (177 × 109/l vs. 75 × 109/l in T/NK-ALL and T-ALL, respectively, P = 0·03). Immunophenotypic analysis demonstrated that CD34, CD45RA and CD33 were more expressed in T/NK-ALL patients, whereas CD8 and terminal deoxynucleotidyl transferase were......
POSTED 11/10/2008 at 11:00 PM --
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE:
The information provided on this
site is intended for your general knowledge only and is not a substitute for
professional medical advice or treatment for specific medical conditions. You
should not use this information to diagnose or treat a health problem or disease
without consulting with a qualified healthcare provider. Please consult your
healthcare provider with any questions or concerns you may have regarding your
condition.
|
|
|
|
|
|
|
|
Featured Product! |
 |
|
Arthrit-Eze |
|
Arthrit-Eze is the most advanced
formula on the market today |
|
It offers potential relief and
rejuvenation for all forms of arthritis, safely, naturally and without side
effects!
NO PRESCRIPTION REQUIRED! |
|
CLICK HERE
for more info... |
|
|
